Redefining
Cancer
Treatment
Redefining
Cancer
Treatment
Pterostilbene supplement prices typically range from £15 to £75 for a month’s supply, based on factors like brand, concentration, and form (capsules, powder, etc.).
Click 
Pterostilbene, a natural demethylated analogue of resveratrol found in blueberries and grapes, demonstrates potent anti-cancer properties through multiple molecular mechanisms. Its superior bioavailability and longer half-life compared to resveratrol make it a promising candidate for metabolic therapy in oncology147.
1. Cell Cycle Arrest
Pterostilbene induces S-phase and G2/M-phase arrest across cancers by:
2. Apoptosis Induction
The compound triggers programmed cell death through:
Endoplasmic reticulum stress (PERK/IRE1/ATF4/CHOP pathways)10
3. Metastasis Suppression
Pterostilbene inhibits cancer spread by:
4. Targeting Cancer Stem Cells (CSCs)
In cervical cancer models, it suppresses CSC traits by:
| Cancer Type | Key Findings |
|---|---|
| Cervical | 50% greater efficacy vs resveratrol in reducing tumorspheres14 |
| Lymphoma (DLBCL) | 58% tumour weight reduction in xenografts via ERK1/2 suppression25 |
| Breast (Triple-negative) | 72% growth inhibition through NF-κB pathway modulation48 |
| Lung | ER stress activation reduces viability by 63% at 50μM10 |
| Cholangiocarcinoma | S-phase arrest with 3-fold p53 increase3 |
Enhanced Bioavailability: 3-4× higher absorption than resveratrol47
Synergy Potential: Combines effectively with chemotherapy/radiotherapy47
Low Toxicity: No significant side effects observed in animal studies23
Preclinical data suggest pterostilbene’s multi-target approach could address key cancer hallmarks while overcoming limitations of conventional therapies. Ongoing research focuses on optimising delivery systems and clinical translation strategies4710.
Pterostilbene’s recommended safe dosage ranges from 50–250 mg daily based on human clinical trials, with variations depending on therapeutic goals and individual factors.
Here’s an overview of current evidence:
Maximum Tolerated Dose: 250 mg/day (125 mg twice daily) demonstrated safety in a 6–8 week randomized controlled trial with hypercholesterolemic patients15.
Typical Maintenance Range: 50–200 mg/day for general health support28.
Weight-Adjusted Guidance:
| Factor | Recommendation |
|---|---|
| Initiation | Start with 50–100 mg daily, gradually increasing38 |
| Cognitive Support | 50 mg/day (animal-study derived)56 |
| Metabolic Targets | 215–430 mg/day for cholesterol/blood sugar management37 |
| Form | Capsules preferred; powder requires precise measurement8 |
Common Side Effects (≤25% incidence at 250 mg/day):
Mild gastrointestinal discomfort
Transient muscle pain
Increased appetite1
Blood Pressure Considerations:
Medication Interactions: Caution with antihypertensives, antidiabetics, and statins due to potential synergistic effects7
Long-Term Use: No data beyond 8 weeks; periodic weight monitoring suggested due to PPAR-γ activation potential1
Preclinical models suggest doses up to 730 mg/day might be tolerated7, but human trials confirm safety only up to 250 mg daily1. The compound exhibits a bell-curve response, with optimal benefits typically below 250 mg/day5. Current evidence supports 50–100 mg as a prudent starting dose, reserving higher doses (200–250 mg) for targeted metabolic interventions under medical supervision.
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Pterostilbene is generally well-tolerated at recommended doses but may cause mild-to-moderate side effects in specific populations. Current evidence from clinical trials establishes safety up to 250 mg/day for 6-8 weeks, though individual responses vary.
Gastrointestinal discomfort: 10-25% incidence (nausea, diarrhoea) at doses ≥125 mg/day15
Musculoskeletal issues: Occasional muscle pain unrelated to statin use58
Appetite changes: Increased hunger reported in 15-25% of users57
Dermatological reactions: Mild itching in ~5% of cases5
Blood pressure fluctuations:
Lipid profile alterations:
| Group | Concerns |
|---|---|
| Hypertensive patients | Requires BP monitoring due to paradoxical effects15 |
| Diabetics | May potentiate glucose-lowering medications13 |
| Liver disease | Potential enzyme interactions; monitor AST/ALT14 |
| Pregnancy/Nursing | Contraindicated due to lack of safety data14 |
Preclinical models show no toxicity even at 3,000 mg/kg in animals7, but human data remains limited beyond 250 mg/day. The compound’s rapid clearance (≤12 hours) minimises accumulation risks6. Long-term safety beyond 8 weeks requires further study, particularly regarding cardiovascular lipid changes28.
Pterostilbene has demonstrated significant therapeutic synergy when combined with various conventional treatments across cancer types and bacterial infections. Clinical and preclinical studies reveal its combinatorial potential through multiple mechanisms:
1. Chemotherapy Enhancement
Docetaxel-resistant lung cancer:
Megestrol acetate (endometrial cancer):
2. Targeted Therapy Combinations
Sunitinib (gastric cancer):
3. Radiation Sensitisation
Triple-negative breast cancer models show:
2.3× increased DNA damage response
Enhanced PARP-1 inhibition8
| Antibiotic | Bacterial Target | Key Benefit |
|---|---|---|
| Polymyxin B | mcr-1-positive E. coli | 60% survival vs 0% monotherapy4 |
| Gentamicin | S. aureus/P. aeruginosa | 5.5→1.25h bactericidal acceleration6 |
Oxidative Stress Amplification: 2.8× ROS increase in gastric cancer models2
Metabolic Pathway Disruption:
Immune Modulation: 3.2× increase in anti-inflammatory cytokines8
Current clinical trials focus on optimizing dosing schedules, with combination therapies generally showing:
38-60% reduced chemotherapeutic doses required
Paradoxical blood pressure effects require monitoring8
These findings position pterostilbene as a versatile adjuvant capable of enhancing conventional therapies while potentially mitigating resistance mechanisms.
Pterostilbene supplementation may influence quality of life through several physiological and psychological pathways, based on current clinical and preclinical evidence:
Neuroprotection: Reduces oxidative stress markers (MDA, 8-OHdG) by 40–60% in neurodegenerative models, potentially slowing cognitive decline in Alzheimer’s/Parkinson’s disease16
Mood Enhancement: Lowers anxiety markers in animal models at 1–2 mg/kg doses through hippocampal-amygdala modulation4
Memory Support: Increases PPAR-α expression in Alzheimer’s models, improving spatial memory retention2
Blood Pressure Management:
Lipid Profile Optimization:
| Parameter | Effect |
|---|---|
| Blood Glucose | 12–15% reduction in diabetic models6 |
| Insulin Sensitivity | AMPK activation improves glucose uptake1 |
| Weight Management | 63% BMI reduction in overweight subjects1 |
Anti-inflammatory Effects:
Exercise Tolerance: Enhanced mitochondrial biogenesis in cardiac tissue6
Gastrointestinal Discomfort: 10–25% incidence at ≥125 mg doses5
Lipid Paradox: 12–15 mg/dL LDL increase in statin users7
Blood Pressure Variability: Requires monitoring in hypertensive patients5
DNA Protection: Mimics calorie restriction effects via adiponectin regulation4
Cellular Repair: Activates sirtuins (SIRT1-3) enhancing DNA damage response7
Quality of life trade-offs centre on dosage optimisation – while 50–100 mg/day generally improves metabolic/cognitive parameters, higher doses (200–250 mg) may introduce cardiovascular monitoring requirements. The compound’s rapid clearance (≤12h) allows daytime cognitive benefits without sleep disruption, though long-term safety beyond 4 months remains unconfirmed. Patients report better disease management capacity but require lipid profile monitoring every 6–8 weeks35.
We’ve done our best to include as much information as possible for this supplement.
If you have any other questions, please send us a message or join our Skool Group and ask our knowledgeable and friendly community.
Pterostilbene is generally available as a dietary supplement in many countries, including the United States, Canada, and parts of Europe. It can be purchased over-the-counter in health food stores, pharmacies, and online retailers. Regulatory status and accessibility may vary by country.
Pterostilbene’s therapeutic benefits show varying efficacy across patient subgroups, with current evidence pointing to specific populations that may derive optimal advantages:
Age:
Middle-aged adults (40–65): Demonstrated 80% compliance in lipid management trials28
Elderly neuroprotection: Preclinical ALS models show functional improvements in aged rodents, though human data remains limited to small ALS cohorts6
Gender:
Female predominance: 71% of trial participants were female, with better LDL response in women (+12.4 mg/dL vs +4.8 mg/dL in males)28
Menopausal metabolic benefits: Enhanced PPAR-γ activation may address oestrogen-deficiency related lipid changes7
Ethnicity:
Caucasian focus: 70% of trial participants, with unknown generalizability to other groups2
Asian population data: Preferential AMPK activation observed in hepatic models7
| Health Status | Benefit Profile |
|---|---|
| Dyslipidaemia | LDL reduction up to 17.1 mg/dL (non-statin users)8 |
| Hypertension | Systolic BP ↓7.8 mmHg at 250 mg/day5 |
| Neurodegeneration | 23.2-point ALSFRS-R improvement in ALS6 |
| Metabolic Syndrome | BMI reduction in 63% of overweight subjects5 |
Statin users: Attenuated LDL response (+4.2 mg/dL vs +17.1 mg/dL in non-users)8
Antihypertensive combos: Additive BP-lowering requires dose adjustment5
Antidiabetic agents: Enhanced glucose control in preclinical models7
Current evidence suggests maximal benefit for:
Middle-aged females with dyslipidaemia
Non-statin using hypertensive patients
Neurodegenerative disease patients under combination therapy
Overweight individuals with PPAR-γ related metabolic dysfunction
Demographic limitations persist, with urgent need for studies in non-Caucasian populations and long-term geriatric applications. Pharmacogenetic factors (e.g., CYP2D6 metabolism) may further modulate responses but remain uncharacterised7.
Pterostilbene’s efficacy can be influenced by several resistance mechanisms identified across cancer types, though its multi-target action partially mitigates these effects.
Key resistance factors include:
MDR1 Overexpression:
Cisplatin-resistant oral cancer cells initially exhibit multidrug resistance via MDR1 upregulation23. Pterostilbene counteracts this by suppressing MDR1 expression and inhibiting AKT phosphorylation, restoring chemosensitivity26.
Pro-Survival Autophagy:
Some cancers activate autophagy as a resistance mechanism. While pterostilbene induces lethal autophagy in oral2, lung4, and bladder cancers6, co-treatment with autophagy inhibitors (3-methyladenine, chloroquine) reverses this effect26. Tumours with defective Atg/Beclin-1/LC3 pathways may resist this mechanism3.
p53 Mutations:
Mutant p53 lines require 2–3× higher pterostilbene doses for equivalent apoptosis induction compared to wild-type p53 cancers1.
Caspase Inhibition:
Pan-caspase inhibitors (Z-VAD-FMK) block pterostilbene-induced apoptosis in oral cancers3, suggesting caspase-dependent pathway mutations could confer resistance.
CHOP Pathway Deficiencies:
NSCLC cells with impaired ERS signalling (PERK/IRE1/ATF4/CHOP) show reduced response to pterostilbene4. CHOP siRNA pretreatment negates pterostilbene’s pro-apoptotic effects in lung cancer models4.
Oncogenic miRNA Overexpression:
Tumours with elevated miR-17/miR-19a/miR-663b levels exhibit reduced PTEN expression and Akt pathway activation1. While pterostilbene suppresses these miRNAs, baseline overexpression may necessitate higher doses1.
EMT Phenotype Maintenance:
Mesenchymal cancers (high Vimentin/ZEB1, low E-cadherin) show diminished response to pterostilbene’s anti-metastatic effects compared to epithelial tumors14.
| Resistance Factor | Pterostilbene’s Countermeasure |
|---|---|
| MDR1 overexpression | Suppresses MDR1 transcription2 |
| Pro-survival autophagy | Converts autophagy to apoptosis via ROS/ERS4 |
| miR-17/miR-19a upregulation | Direct miRNA inhibition restores PTEN1 |
Preclinical evidence suggests combining pterostilbene with ERS inducers (thapsigargin)4 or HDAC inhibitors1 may overcome resistance. Its ability to simultaneously target MDR1, autophagy, and apoptotic pathways provides a multi-pronged approach against conventional resistance mechanisms246.
Pterostilbene has demonstrated significant potential in preclinical studies, revealing multifaceted anticancer mechanisms and favourable pharmacokinetic properties.
Here’s an overview of key findings across experimental models:
Bioavailability: Exhibits 3–4× higher absorption than resveratrol due to its dimethylated structure17.
Metabolism: Undergoes phase II glucuronidation in rats (serum t₁/₂: 1.73 h; urine t₁/₂: 17.3 h)13.
Dose Range: Effective anticancer activity observed at 1–100 μg/mL in vitro and 50 mg/kg in mouse xenografts125.
1. Cell Cycle Arrest
Induces S-phase arrest in lung squamous cell carcinoma (H520) via cyclin A2/E1 suppression2.
Triggers G2/M-phase arrest in colorectal cancer (CL187) through p53 upregulation5.
2. Apoptosis Induction
Activates intrinsic pathways (caspase-9/-3) in lung cancer models2.
Enhances extrinsic pathways (Fas/FasL) in oral squamous cell carcinoma (SCC-9)5.
3. Metastasis Suppression
Reduces MMP-2/-9 expression by 65–80% in SCC-9 cells5.
Inhibits NF-κB DNA binding activity by 70% through ΙκBα phosphorylation blockade5.
4. Antioxidant Effects
| Model Type | Key Findings |
|---|---|
| Lung SqCC (H520 xenografts) | 50 mg/kg every other day reduced tumour volume by 58%2 |
| Colorectal CL187 xenografts | 72% tumour weight reduction via TDP1/TOP1 inhibition5 |
| Pancreatic/Breast cancers | 50–60% growth inhibition in nude mice6 |
| Oral SCC-9 | 80% suppression of cell migration via ERK/JNK/p38 modulation5 |
Acute Toxicity: No organ weight changes or mortality at 250 mg/kg (rats)1.
Chronic Exposure: Maintained normal liver/kidney function markers over 8 weeks25.
Synergy Potential: Enhances chemotherapy efficacy without additive toxicity in xenografts27.
Preclinical data highlight pterostilbene’s superior therapeutic index compared to resveratrol, particularly in colorectal (IC₅₀ 22.4 vs 43.8 μmol/L) and lung cancer models57. While phase II metabolism may limit bioavailability, its multi-target action against proliferation, metastasis, and oxidative stress positions it as a promising adjuvant for oncology applications.
Information on active clinical trials can be found here.
Pterostilbene’s efficacy shows genetic and epigenetic dependencies, with preclinical evidence identifying biomarkers influencing its therapeutic effects across cancer types. These markers primarily involve metabolic enzymes, epigenetic regulators, and oncogenic pathway components:
CYP2C9:
Strong inhibition (IC₅₀ = 0.12 μM) suggests slow metabolisers may experience enhanced bioavailability3
CYP2C9 variants (*2/*3 alleles) could modulate systemic exposure
UGT1A1/1A3:
Primary glucuronidation enzymes affecting hepatic clearance5
UGT1A1 polymorphisms (e.g., UGT1A1*28) may reduce inactivation rates
| Marker | Mechanism | Cancer Type |
|---|---|---|
| miR-663b | Downregulation induces apoptosis | Endometrial |
| miR-17/miR-19a | Suppression reactivates PTEN/AKT pathway | Liver/Prostate |
| DNA methylation | Demethylates ERα/PTEN promoters | Breast/Ovarian |
STAT3 phosphorylation status:
PTEN expression:
Pterostilbene efficacy amplified in PTEN-deficient cancers via acetylation-mediated reactivation4
E-cadherin/Vimentin ratio:
Epithelial tumours (high E-cadherin) show better EMT reversal than mesenchymal phenotypes4
p53 status:
Preclinical models suggest combinatorial approaches targeting these markers could enhance efficacy – e.g., CYP2C9 slow metabolizers might benefit from lower doses, while PTEN-null cancers may require HDAC inhibitor combinations. Clinical validation of these biomarkers remains pending, particularly regarding pharmacogenomic influences on dosing and toxicity profiles.
Could a humble heartburn pill hold the key to slashing cancer metastasis and boosting survival? Once relegated to pharmacy shelves
Website designed in collaboration with Simon Lown for Metabolic Therapy Ltd
Apoptosis, or programmed cell death, is a natural process where cells self-destruct when they are damaged or no longer needed. This is crucial for maintaining healthy tissues and preventing diseases like cancer.
Drugs and supplements that induce apoptosis help eliminate cancerous cells by triggering this self-destruct mechanism, ensuring that harmful cells are removed without damaging surrounding healthy tissue.
Understanding and harnessing apoptosis is vital in the fight against cancer, as it targets the root cause of the disease at the cellular level.
Cell proliferation is the process by which cells grow and divide to produce more cells. While this is essential for growth and healing, uncontrolled cell proliferation can lead to cancer.
Drugs and supplements that inhibit cell proliferation help prevent the rapid multiplication of cancerous cells, slowing down or stopping the progression of the disease.
By targeting the mechanisms that drive cell division, these treatments play a vital role in controlling and potentially eradicating cancer.
Cancer cells often hijack specific biological pathways to grow and spread. Drugs and supplements that target these pathways can disrupt the cancer cell’s ability to survive and multiply.
By focusing on the unique mechanisms that cancer cells use, these treatments can be more effective and cause fewer side effects compared to traditional therapies.
Targeting specific pathways is a key strategy in precision medicine, offering a tailored approach to combat cancer at its core.
Angiogenesis is the process by which new blood vessels form, supplying nutrients and oxygen to tissues. Cancer cells exploit this process to fuel their growth and spread.
Drugs and supplements that inhibit angiogenesis can effectively starve cancer cells by blocking the formation of these new blood vessels.
By cutting off the supply lines that tumors rely on, angiogenesis inhibitors play a crucial role in controlling and potentially shrinking cancerous growths.
Immunotherapy harnesses the power of the body’s immune system to combat cancer. By boosting or restoring the immune system’s natural ability to detect and destroy cancer cells, immunotherapy offers a targeted and effective approach to treatment.
Drugs and supplements that support immunotherapy can enhance the immune response, making it more efficient at identifying and attacking cancer cells.
This innovative approach not only helps in treating cancer but also reduces the risk of recurrence, providing a powerful tool in the fight against this disease.
Inflammation is the body’s natural response to injury or infection, but chronic inflammation can contribute to the development and progression of cancer.
Drugs and supplements with anti-inflammatory properties help reduce inflammation, thereby lowering the risk of cancer and other chronic diseases.
By targeting the inflammatory processes, these treatments can help maintain a healthier cellular environment and prevent the conditions that allow cancer to thrive.
